KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Net Cash Flow (2016 - 2025)

Abbott Laboratories' Net Cash Flow history spans 17 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 612.77% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $835.0 million, up 2.33%, while the annual FY2025 figure was $835.0 million, 2.33% up from the prior year.
  • Net Cash Flow for Q4 2025 was $1.0 billion at Abbott Laboratories, up from $570.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.3 billion in Q2 2022 and bottomed at -$2.1 billion in Q1 2022.
  • The 5-year median for Net Cash Flow is $439.0 million (2021), against an average of $96.2 million.
  • The largest annual shift saw Net Cash Flow tumbled 269.71% in 2022 before it surged 612.77% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $510.0 million in 2021, then tumbled by 53.53% to $237.0 million in 2022, then plummeted by 31.65% to $162.0 million in 2023, then dropped by 12.96% to $141.0 million in 2024, then soared by 612.77% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Net Cash Flow are $1.0 billion (Q4 2025), $570.0 million (Q3 2025), and $368.0 million (Q2 2025).